Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Research

Transcriptomics analysis revealed that TAZ regulates the proliferation of KIRC cells through mitophagy

Authors: Zhen He, Jianxi Shi, Bing Zhu, Zhentao Tian, Zhihong Zhang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Transcriptional Co-Activator with PDZ-Binding Motif (TAZ, also known as WWTR1) is a downstream effector of the Hippo pathway, involved in the regulation of organ regeneration and cell differentiation in processes such as development and regeneration. TAZ has been shown to play a tumor-promoting role in various cancers. Currently, many studies focus on the role of TAZ in the process of mitophagy. However, the molecular mechanism and biological function of TAZ in renal clear cell carcinoma (KIRC) are still unclear. Therefore, we systematically analyzed the mRNA expression profile and clinical data of KIRC in The Cancer Genome Atlas (TCGA) dataset. We found that TAZ expression was significantly upregulated in KIRC compared with normal kidney tissue and was closely associated with poor prognosis of patients. Combined with the joint analysis of 36 mitophagy genes, it was found that TAZ was significantly negatively correlated with the positive regulators of mitophagy. Finally, our results confirmed that high expression of TAZ in KIRC inhibits mitophagy and promotes KIRC cell proliferation. In conclusion, our findings reveal the important role of TAZ in KIRC and have the potential to be a new target for KIRC therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Stat 2021 CA Cancer J Clin. 2021;71(1):7–33. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Stat 2021 CA Cancer J Clin. 2021;71(1):7–33.
2.
go back to reference Capitanio U, Montorsi F. Ren Cancer Lancet. 2016;387(10021):894–906. Capitanio U, Montorsi F. Ren Cancer Lancet. 2016;387(10021):894–906.
3.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer Incidence and Mortality Worldwide: sources, methods and major patterns in Globocan 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer Incidence and Mortality Worldwide: sources, methods and major patterns in Globocan 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
6.
go back to reference Chai D, Shan H, Wang G, Li H, Fang L, Song J, Zhang Q, Bai J, Zheng J. Aim2 is a potential therapeutic target in human renal carcinoma and suppresses its Invasion and Metastasis Via enhancing Autophagy induction. Exp Cell Res. 2018;370(2):561–70.CrossRefPubMed Chai D, Shan H, Wang G, Li H, Fang L, Song J, Zhang Q, Bai J, Zheng J. Aim2 is a potential therapeutic target in human renal carcinoma and suppresses its Invasion and Metastasis Via enhancing Autophagy induction. Exp Cell Res. 2018;370(2):561–70.CrossRefPubMed
7.
go back to reference Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X, Onorati A, Kalavacharla A, Kim T, Zhen CJ, Kadri S, Segal JP, Gimotty PA, Davis LE. Amaravadi. Autophagy inhibition to Augment Mtor inhibition: a phase I/Ii trial of Everolimus and Hydroxychloroquine in patients with previously treated renal cell carcinoma. Clin Cancer Res. 2019;25(7):2080–87.CrossRefPubMedPubMedCentral Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X, Onorati A, Kalavacharla A, Kim T, Zhen CJ, Kadri S, Segal JP, Gimotty PA, Davis LE. Amaravadi. Autophagy inhibition to Augment Mtor inhibition: a phase I/Ii trial of Everolimus and Hydroxychloroquine in patients with previously treated renal cell carcinoma. Clin Cancer Res. 2019;25(7):2080–87.CrossRefPubMedPubMedCentral
8.
go back to reference Patel SH, Camargo FD, Yimlamai D. Hippo Signaling in the liver regulates organ size, cell fate, and carcinogenesis. Gastroenterology. 2017;152(no 3):533–45.CrossRefPubMed Patel SH, Camargo FD, Yimlamai D. Hippo Signaling in the liver regulates organ size, cell fate, and carcinogenesis. Gastroenterology. 2017;152(no 3):533–45.CrossRefPubMed
9.
go back to reference White SM, Avantaggiati ML, Nemazanyy I, Di Poto C, Yang Y, Pende M, Gibney GT, Ressom HW, Field J, Atkins MB, Yi C. Yap/Taz inhibition induces metabolic and Signaling Rewiring resulting in Targetable vulnerabilities in Nf2-Deficient tumor cells. Dev Cell 49, no. 3 (2019): 425– 43.e9. White SM, Avantaggiati ML, Nemazanyy I, Di Poto C, Yang Y, Pende M, Gibney GT, Ressom HW, Field J, Atkins MB, Yi C. Yap/Taz inhibition induces metabolic and Signaling Rewiring resulting in Targetable vulnerabilities in Nf2-Deficient tumor cells. Dev Cell 49, no. 3 (2019): 425– 43.e9.
10.
go back to reference Yang WH, Ding CC, Sun T, Rupprecht G, Lin CC, Hsu D. Chi. The Hippo Pathway Effector Taz regulates ferroptosis in renal cell carcinoma. Cell Rep. 2019;28(10):2501–08e4.CrossRefPubMedPubMedCentral Yang WH, Ding CC, Sun T, Rupprecht G, Lin CC, Hsu D. Chi. The Hippo Pathway Effector Taz regulates ferroptosis in renal cell carcinoma. Cell Rep. 2019;28(10):2501–08e4.CrossRefPubMedPubMedCentral
12.
go back to reference Montava-Garriga L, Ganley IG. Outstanding questions in Mitophagy: what we do and do not know. J Mol Biol. 2020;432(1):206–30.CrossRefPubMed Montava-Garriga L, Ganley IG. Outstanding questions in Mitophagy: what we do and do not know. J Mol Biol. 2020;432(1):206–30.CrossRefPubMed
13.
go back to reference Kulikov AV, Luchkina EA, Gogvadze V, Zhivotovsky B. Mitophagy: link to Cancer Development and Therapy. Biochem Biophys Res Commun. 2017;482(3):432–39.CrossRefPubMed Kulikov AV, Luchkina EA, Gogvadze V, Zhivotovsky B. Mitophagy: link to Cancer Development and Therapy. Biochem Biophys Res Commun. 2017;482(3):432–39.CrossRefPubMed
15.
go back to reference Su L, Zhang J, Gomez H, Kellum JA, Peng Z. Mitochondria Ros and Mitophagy in Acute Kidney Injury. Autophagy 19, no. 2 (2023): 401– 14. Su L, Zhang J, Gomez H, Kellum JA, Peng Z. Mitochondria Ros and Mitophagy in Acute Kidney Injury. Autophagy 19, no. 2 (2023): 401– 14.
16.
go back to reference Hartleben B, Gödel M, Meyer-Schwesinger C, Liu S, Ulrich T, Köbler S, Wiech T, Grahammer F, Arnold SJ, Lindenmeyer MT, Cohen CD, Pavenstädt H, Kerjaschki D, Mizushima N, Shaw AS, Walz G. Huber. Autophagy influences glomerular Disease susceptibility and maintains Podocyte Homeostasis in Aging mice. J Clin Invest. 2010;120(4):1084–96.CrossRefPubMedPubMedCentral Hartleben B, Gödel M, Meyer-Schwesinger C, Liu S, Ulrich T, Köbler S, Wiech T, Grahammer F, Arnold SJ, Lindenmeyer MT, Cohen CD, Pavenstädt H, Kerjaschki D, Mizushima N, Shaw AS, Walz G. Huber. Autophagy influences glomerular Disease susceptibility and maintains Podocyte Homeostasis in Aging mice. J Clin Invest. 2010;120(4):1084–96.CrossRefPubMedPubMedCentral
17.
go back to reference Guan Y, Wang Y, Li B, Shen K, Li Q, Ni Y, Huang L. Mitophagy in Carcinogenesis, Drug Resistance and Anticancer therapeutics. Cancer Cell Int. 2021;21(1):350.CrossRefPubMedPubMedCentral Guan Y, Wang Y, Li B, Shen K, Li Q, Ni Y, Huang L. Mitophagy in Carcinogenesis, Drug Resistance and Anticancer therapeutics. Cancer Cell Int. 2021;21(1):350.CrossRefPubMedPubMedCentral
18.
go back to reference Juan WC, Hong W. Targeting the Hippo Signaling Pathway for tissue regeneration and Cancer therapy. Genes (Basel). 2016;7:9.CrossRef Juan WC, Hong W. Targeting the Hippo Signaling Pathway for tissue regeneration and Cancer therapy. Genes (Basel). 2016;7:9.CrossRef
19.
go back to reference Harvey KF, Zhang X, Thomas DM. The Hippo Pathway and Human Cancer. Nat Rev Cancer. 2013;13(4):246–57.CrossRefPubMed Harvey KF, Zhang X, Thomas DM. The Hippo Pathway and Human Cancer. Nat Rev Cancer. 2013;13(4):246–57.CrossRefPubMed
21.
go back to reference Fan S, Price T, Huang W, Plue M, Warren J, Sundaramoorthy P, Paul B, Feinberg D, MacIver N, Chao N, Sipkins D, Kang Y. Pink1-Dependent Mitophagy regulates the Migration and Homing of multiple myeloma cells Via the Mob1b-Mediated Hippo-Yap/Taz pathway. Adv Sci (Weinh). 2020;7(5):1900860.CrossRefPubMed Fan S, Price T, Huang W, Plue M, Warren J, Sundaramoorthy P, Paul B, Feinberg D, MacIver N, Chao N, Sipkins D, Kang Y. Pink1-Dependent Mitophagy regulates the Migration and Homing of multiple myeloma cells Via the Mob1b-Mediated Hippo-Yap/Taz pathway. Adv Sci (Weinh). 2020;7(5):1900860.CrossRefPubMed
22.
go back to reference Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim J. Actin remodeling confers Braf Inhibitor Resistance to Melanoma Cells through Yap/Taz activation. Embo j. 2016;35(5):462–78.CrossRefPubMed Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim J. Actin remodeling confers Braf Inhibitor Resistance to Melanoma Cells through Yap/Taz activation. Embo j. 2016;35(5):462–78.CrossRefPubMed
Metadata
Title
Transcriptomics analysis revealed that TAZ regulates the proliferation of KIRC cells through mitophagy
Authors
Zhen He
Jianxi Shi
Bing Zhu
Zhentao Tian
Zhihong Zhang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11903-9

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine